Rethinking access to medicines: towards a refined legal framework for medicine shortages KU Leuven
Rethinking access to medicines: towards a refined legal framework for medicine shortages
Rethinking access to medicines: towards a refined legal framework for medicine shortages
Over the past few years, researchers and clinicians in MS have made substantial progress in understanding and treating multiple sclerosis (MS). First, more than 110 genetic risk factors for MS have been identified. These risk factors point to a crucial role of the immune system and indicate new targets for treatments. Secondly, we start to understand some of the important differences between patients that are remarkable in MS. For others, ...
Many childhood-onset diseases used to be lethal. Improved life expectancy yield that most patients can survive into adulthood, to date. However, survivors of childhood-onset diseases often develop morbidities that suggest accelerated aging. Congenital heart disease is a typical example of a childhood-onset disease. It is the most common birth defect, comprising a spectrum of mild, moderate and complex heart defects. Several age-related ...
SulTAn (SULfonamides and Trimethoprim combinations in ANimals)
Due to the pending constraints for veterinarians to use antibiotics critically important for human health in Europe, the relative use of first-line antibiotics such as the combination of trimethoprim (TMP) and sulfonamides (S) will increase in all animal species in coming years. ...
This research project will develop explainable and interactive artificial intelligence (AI) for the analysis of large and complex clinical data, in order to improve respiratory medicine. On the one hand, we will explore and develop novel AI-based models for diagnostic and prognostic decision support at multidisciplinary board discussions, which are the gold standard for complex clinical decision making across medical disciplines. We will ...
The imminent introduction of new therapies for both Crohn’s disease (CD) and ulcerative colitis (UC), will have a huge impact on our clinical practice in the coming years. However, it is anticipated that clinical response to each of these agents will vary significantly between individuals. Furthermore, these new therapies are expensive and long-term use may be associated with adverse events. Another important drawback for treatment with ...